◈ Nootpedia
Compact view
Research pass: thorough Supplement · Capsule OPTIONAL-ADD MEDIUM-HIGH

Urolithin A

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM-HIGH

This is the most-evidenced "longevity supplement" available OTC as of May 2026 — three distinct human RCTs (Andreux 2019, Liu 2022, Singh 2022 ATLAS-derived) consistently show measurable improvements in mitochondrial gene expression, plasma C-acylcarnitine biomarkers, and modest muscle endurance gains in older adults at 500–1000 mg/day. **Effect size is real but modest, age-stratified (best signal in 50+), and chronic (4+ months for muscle endpoints).** For Dylan at 20: low-priority because (a) endogenous mitochondrial quality is already near peak, (b) muscle endurance signal in young athletes is unstudied and likely below detection threshold against training-driven adaptation, (c) ~30–40% of Western adults are urolithin "non-producers" — Dylan's producer status is unknown until 23andMe + microbiome testing or direct urinary metabolite assay. Verdict moves to **STRONG-CANDIDATE at 30+** and STRONG-CANDIDATE today *if* microbiome non-producer status confirmed. **What would change verdict:** confirmed urinary non-producer status post-pomegranate-load test → upgrade to STRONG-CANDIDATE now (specific physiological gap to fill); positive young-athlete RCT readout → upgrade.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20–30, brain-priority, high cognitive workload + MMA athlete (Dylan-archetype)
    OPTIONAL-ADD

    MEDIUM-HIGH evidence confidence, LOW expected delta. Rationale: trial evidence is real and replicated, but age-stratified — young trained mitochondria have less room for benefit. Dylan's profile sits opposite the trial demographic (young, trained vs trial's old, sedentary). Higher-yield levers exist: sleep, training periodization, V4 core stack. Best-case use: test microbiome producer status first; if non-producer confirmed → STRONG-CANDIDATE with clear physiological rationale; if producer status unknown or confirmed producer → defer to age 30+. Run a single 4-month 500 mg trial post-bloodwork if curious; track Whoop HRV + cardio session RPE.

  • 30–50, executive maintenance
    STRONG-CANDIDATE

    MEDIUM-HIGH confidence. Endogenous mitochondrial quality begins measurable decline; trial demographic increasingly applicable. 500–1000 mg/day continuous, monitor C-acylcarnitines if labs available. Particularly relevant for sedentary or sub-optimally-active 40+ adults.

  • 50+, mild metabolic / muscle decline
    PRIMARY-PICK

    among longevity supplements, HIGH confidence. This is the trial demographic. Liu 2022 + Singh 2022 + Andreux 2019 specifically validated this population. 1000 mg/day, continuous, expect 3–4 months for muscle endpoints. Pair with resistance training for additive effect. Strongest indication of any age group.

  • Anxiety-prone
    NEUTRAL

    No anxiogenic signal; no anxiolytic signal. Wrong category.

  • High athletic load, tested status (WADA-relevant)
    OPTIONAL-ADD

    Not on WADA prohibited list. Same young-athlete caveat applies — likely subtle benefit.

  • Sleep-disordered
    NEUTRAL

    No sleep effects reported. Some users anecdotally report improved sleep quality (likely secondary to better daytime energy / training recovery). Not a sleep treatment.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    MEDIUM confidence. Mitochondrial-quality support during recovery is mechanistically reasonable; no targeted RCT in this population. Low-risk addition during prolonged recovery phases.

  • Strength/anabolic-focused
    NEUTRAL-NEGATIVE

    UA's effect is on muscle *endurance*, not strength (Singh 2022 explicitly missed grip strength endpoint). Wrong category for hypertrophy goals.

▸ Subjective experience (deep)

Honest summary across community + trial subjective endpoints for healthy adults running 500–1000 mg/day for 1–6 months:

  • First week: Nothing. UA is a chronic compound with no acute pharmacology. Users reporting day-1 effects are confused, placebo, or unrelated.
  • Weeks 2–4: Still nothing for most. Some users report a vague "cleaner energy" or slightly improved cardio session feel; indistinguishable from training-week variability or placebo.
  • Weeks 4–8: Emerging signal in a subset. Cardio recovery within sessions ("could push one more round at the same RPE") is the most-reported early signal. Subjective post-training soreness reduction. Energy stability through cognitive workdays.
  • Weeks 8–16 (the trial window for muscle endpoints): Peak signal. Users matching the trial demographic (40+, sedentary or low-trained) show the clearest functional changes. Younger trained users (Dylan's profile) more often report "subtle or nothing."
  • Months 4–6+: Cumulative effects continue to develop (Liu 2022 ran 16 weeks and saw progression through the cycle). The 4-month mark is where Singh 2022 found knee extension fatigue resistance gain.
  • Cycle off: No withdrawal, no rebound. Effects fade gradually over 4–8 weeks as endogenous mitochondrial quality returns to baseline.

Honesty about variability: UA produces subtle, cumulative, age-dependent effects. There is no characteristic "feel" — no stim, no nootropic clarity, no acute lift. Vendor marketing showing "felt the difference in 2 weeks" testimonials is overstated. Trials needed 16 weeks at 1000 mg in a population primed to respond (older sedentary adults with measurable mitochondrial decline at baseline) to detect ~12% effect sizes on functional endpoints. Young athletes with already-optimal mitochondrial quality should expect minimal subjective signal.

For Dylan specifically: if he runs UA, the most likely outcomes are (1) zero subjective effect (most likely given his profile), (2) mild improvement in long-cardio session feel (possible if he's a non-producer), (3) clear improvement (unlikely given age + training status). Bloodwork-based decision is the right framework — the most detectable signal would be plasma C-acylcarnitine reductions, which require specialty metabolomic panels not in standard labs.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: minimal / not reported. UA targets a quality-control pathway (mitophagy) that does not appear to desensitize with chronic activation. Cell-culture and rodent data show sustained effect over multi-month dosing.
  • Recommended cycle: continuous. No cycling required for mechanism. Some users cycle 12 weeks on, 4 weeks off for budget reasons; not evidence-based.
  • Reset protocol: Not needed. If cycling off, plasma UA falls to undetectable within ~3–4 days; downstream mitochondrial improvements fade over 4–8 weeks.
  • Long-term cumulative use: Mitopure has been on-market since 2020; long-term user data (5+ years) shows no emerging safety signals. Theoretical concerns about chronic mitophagy activation remain unstudied at multi-decade horizons.
▸ Stacking deep dive

Synergistic with

  • mots-c: Different mitochondrial layer — MOTS-c is metabolic-signaling (AMPK activation, exercise-mimetic), UA is quality-control (mitophagy + biogenesis). Mechanistically complementary; no overlap. For Dylan: both are OPTIONAL-ADD at 20; running together creates attribution problems but no biological conflict.
  • ss-31 (Elamipretide): Cardiolipin stabilization + ETC efficiency. Different mitochondrial layer (structural/functional vs turnover). Mitochondrial peptide stack triad: UA + SS-31 + NAD+ precursors is the canonical "mitochondrial longevity" stack architecture used in 50+ protocols.
  • nad-plus (NMN, NR, NAD+ precursors): Substrate for sirtuin/PARP activity. Synergistic with UA via different mechanism (substrate provision vs damaged-mitochondria clearance). Convergent at downstream PGC-1α/SIRT1 axis. Standard longevity-stack pairing.
  • spermidine: Both induce autophagy (spermidine is broad-spectrum autophagy inducer; UA is selective mitophagy). Mechanistically additive; some longevity protocols stack both.
  • Coenzyme Q10 / ubiquinol: Electron transport chain support. Different mechanism from UA but compatible — Q10 supports the function of mitochondria; UA improves the population quality.
  • Idebenone: Synthetic Q10 analog. Same logic as ubiquinol — different layer, compatible.
  • Creatine (Dylan already running): Phosphocreatine energy buffering. Compatible; no interaction.
  • Cardio training itself: UA's mitophagy effect plus exercise-induced mitochondrial biogenesis are mechanistically additive. Best-case use of UA is in trained populations who are already producing the exercise stimulus.

Avoid stacking with

  • No documented contraindications for stacking. UA is unusually clean on interaction profile.
  • Theoretical caution: stacking with high-dose anti-inflammatory regimens (concurrent NLRP3-targeted drugs, high-dose curcumin + boswellia + omega-3 megadose) is unstudied — likely fine but no data.

Neutral / safe co-administration

  • All V4 daily core supplements (DHA, magnesium, citicoline, NAC, PS, curcumin, rhodiola, theanine, glycine/L-tryptophan, D3/K2, beta-alanine, vitamin C)
  • All V5 candidate cognitive compounds (modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, taurine, astaxanthin)
  • All cycled peptides Dylan is considering (Cerebrolysin, MOTS-c, BPC-157, TB-500)
  • Caffeine, creatine, electrolytes, standard sports nutrition
  • Pomegranate, walnuts, berries — actually mechanistically synergistic if Dylan happens to be a microbiome producer
▸ Drug interactions deep dive
  • CYP enzymes: UA is glucuronidated and sulfated (UGT1A and SULT pathways) for clearance. No significant CYP induction or inhibition documented in clinical PK studies. Does not affect modafinil (CYP3A4), oral contraceptive metabolism, warfarin, or stimulant clearance.
  • Hormonal contraceptives: No interaction (not relevant for Dylan).
  • Anticoagulants: No documented interaction. Theoretical antiplatelet effect at very high doses (preclinical only); not clinically significant.
  • Alcohol: No specific interaction. Alcohol independently impairs mitochondrial function; UA may partially counter chronic alcohol mitochondrial damage (preclinical only).
  • Caffeine: No interaction.
  • NSAIDs / acetaminophen: No documented interaction.
  • Statins: No documented interaction. Theoretical: statins impair mitochondrial Q10 synthesis and produce muscle complaints; UA's mitochondrial-quality-control mechanism could theoretically offset statin-induced mitochondrial dysfunction. Not validated in trials but mechanistically plausible — interesting hypothesis for the future.
  • Other peptides / nootropics in Dylan's stack: No interactions documented.
▸ Pharmacogenomics
  • Microbiome metabotype is the dominant pharmacogenomic factor — but it's not host genetics, it's gut bacteria composition. ~30–40% of Western adults are metabotype 0 (non-producers); ~25–35% metabotype B (urolithin-B-dominant); ~30–35% metabotype A (urolithin-A producers). Metabotype is determined by Gordonibacter / Ellagibacter abundance, which is influenced by:
    • Diet pattern: Mediterranean / high-fiber / nut-rich → producer-favorable; Western / processed / low-polyphenol → non-producer-favorable
    • Antibiotic exposure history: broad-spectrum antibiotics deplete Gordonibacter; recovery is incomplete in many adults
    • Age: producer status declines with age (older adults more often non-producers)
    • Geographic / ethnic patterns: varies; Mediterranean / Asian populations often higher producer rates than Northern European / North American cohorts
  • For Dylan: unknown without testing. Action item: if he's interested in UA, the cleanest test is a urinary urolithin glucuronide assay 24–48 hours after a standardized pomegranate juice load (250–500 mL high-ellagitannin pomegranate juice). Specialty labs (ZRT, Genova, Doctor's Data) can run this. Less rigorous: 4-day pomegranate-juice trial with subjective effect tracking — but UA effects are too subtle and chronic for this to discriminate.
  • Host genetic SNPs (limited relevance):
    • UGT1A polymorphisms (urolithin glucuronidation enzyme) — variants modulate UA clearance rate; clinically relevant variants are rare. No specific UA-dosing implications established.
    • No CYP polymorphism relevance (UA not metabolized by CYPs).
    • Mitochondrial haplogroup variants: speculative — different mtDNA haplogroups may have different baseline mitochondrial efficiency, theoretically modulating UA response window. No data.
  • 23andMe pull (June 2026) action items: UGT1A1 status (Gilbert syndrome variants) — no direct UA implications but worth flagging if present. No microbiome data from 23andMe.

Summary: The single most important "pharmacogenomic" factor for UA is microbiome producer status, which 23andMe cannot tell you. A urinary metabolite test post-pomegranate load is the gold-standard discriminator and would meaningfully sharpen Dylan's verdict.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC branded (premium) Mitopure (Timeline Nutrition / Amazentis) $80/mo (500 mg/day) — $130/mo (1000 mg/day) high The only formulation used in published RCTs. Proprietary processing claimed to improve bioavailability. Subscription discounts ~15%. Powder, capsule, soft chew formats. Default if budget allows.
OTC generic Renue By Science (renuebyscience.com) $40–55/mo (500 mg/day) medium-high Pure UA powder + capsule options. Third-party tested with COA. Reliable supplier in longevity-supplement space. ~50% Mitopure cost. Best value option.
OTC generic Double Wood Supplements (doublewoodsupplements.com / Amazon) $30–45/mo (500 mg/day) medium Lower-tier pricing, COA on request, mixed community reviews on lot consistency. Cheapest reliable generic option.
OTC generic ProHealth Longevity $50–70/mo medium-high Established longevity vendor; UA included in stack-bundle pricing options.
OTC generic Amazentis direct generic equivalents varies varies Several smaller longevity vendors (Lifespan.io affiliates, Donotage, etc.) sell generic UA at varying prices. COA verification critical for unfamiliar vendors.
Pomegranate / dietary loading (if producer) Whole pomegranates, walnuts, raspberries dietary cost n/a Only effective if Dylan is a metabotype A producer. Without confirmation, dietary loading is a low-yield strategy for UA exposure. Still beneficial for other polyphenol/fiber reasons.
Avoid Unverified Amazon third-party sellers varies low Quality control is poor; many "urolithin A" Amazon listings have been tested and found to contain minimal actual UA. Verify COA + third-party testing for any non-established vendor.

Cost math for Dylan:

  • Mitopure 500 mg × 4 months trial: ~$320. Premium option, trial-validated formulation.
  • Renue By Science generic 500 mg × 4 months trial: ~$160–220. Best value with reasonable confidence.
  • Double Wood 500 mg × 4 months trial: ~$120–180. Cheapest credible option.
  • Annual continuous use at Mitopure 500 mg: ~$960/yr.
  • Annual continuous use at Renue 500 mg: ~$480–660/yr.
  • For an OPTIONAL-ADD compound with unclear delta in young athletes: $480–960/yr is meaningful. Recommendation if Dylan pursues UA: start with Renue generic for first 4-month trial; upgrade to Mitopure only if clear effect signal warrants.

Quality verification:

  • COA: ≥98% purity by HPLC, mass spec confirmation
  • Third-party testing for heavy metals, microbial contamination
  • Batch traceability
  • Reconstitution / dissolution test for capsule formats (visible particulate-free)
  • For powder: should be off-white to pale yellow; dark brown or strongly discolored powder suggests degradation or impurity

Cold chain: Not required. UA is shelf-stable at room temperature for 2+ years properly packaged. Refrigerate if humid environment to prevent moisture absorption (powder forms).

▸ Biomarkers to track (deep)

Baseline (before first cycle)

  • Plasma C-acylcarnitine panel (specialty metabolomic — C2, C16, C18, C18:1) — gold-standard UA-responsiveness biomarker. Genova, Doctor's Data, or research-grade panels. Not in standard CMP.
  • Urinary urolithin A glucuronide post-pomegranate-load — definitive metabotype assay. ZRT or specialty lab. Optional but high-information.
  • CBC, CMP, lipid panel, hsCRP, fasting glucose, HOMA-IR, HbA1c — full V4-baseline bloodwork (already planned for June 2026)
  • Body composition (DEXA preferred) — relevant for muscle endpoint tracking
  • Cardio benchmark: time-to-exhaustion or 5K time at fixed effort
  • Subjective baseline log: sleep, RPE during sparring, recovery quality, weekly fatigue impression
  • Whoop / Oura HRV trend (Dylan owns) — autonomic baseline

During cycle (4–16 weeks)

  • Subjective log: weekly cardio session RPE, recovery quality, energy stability
  • HRV trend (Whoop / Oura) — most accessible objective signal
  • Body composition mid-cycle if pursuing muscle endpoint

Post-cycle (4 months)

  • Repeat plasma C-acylcarnitines (if available pre/post) — cleanest mechanism confirmation
  • Repeat hsCRP — anti-inflammatory layer
  • Repeat cardio benchmark (with caveat: training adaptation will dominate signal)
  • Subjective recap: worth continuing? clear signal vs nothing?

Decision rule: if pre/post acylcarnitine panel shows meaningful drop (>15% reduction in C16/C18) AND subjective cardio/recovery signal positive → continue. If no biomarker signal AND subjective ambiguous → drop until age 30+ revisit.

▸ Controversies / open debates Live debate
  • Effect size in young trained populations is genuinely unknown. All published RCTs targeted older or sedentary populations. The mechanism (mitophagy) should still operate in young trained mitochondria, but the room for benefit is narrower because mitochondrial quality is already near peak. Vendor marketing implies broad-population benefit; trial evidence does not. Honest framing for Dylan: real evidence exists, but it doesn't apply directly to his demographic.
  • Microbiome producer status as decision-relevant variable. ~30–40% of adults are non-producers. Vendor marketing rarely emphasizes this — it's their competitive moat (direct supplementation bypasses microbiome, which is genuinely useful for non-producers). For producer-status individuals, dietary pomegranate/walnuts may be partially redundant with supplementation. The cleanest research question for Dylan is "what's my producer status?" not "should I take UA?"
  • Mitopure formulation premium vs generic UA. Amazentis claims proprietary processing improves bioavailability over commodity UA powder. Some independent dissolution / bioavailability data supports modest improvement, but the gap is not enormous. Generic UA is probably 80–90% as effective per dose — pay the Mitopure premium if you're risk-averse and budget allows, otherwise generic is reasonable.
  • Cognitive / cardiac claims are preclinical-only. Vendor and longevity-community framing increasingly extends UA to "brain health" and "heart health" based on rodent data and mechanism. No human RCT has tested cognition or cardiovascular endpoints. The muscle / mitochondrial-biomarker evidence is solid; everything else is extrapolation.
  • "Senolytic" claims are overstated. Some preclinical UA data shows mild senolytic activity; this is not the primary mechanism, and human senolytic activity is unconfirmed. Stacking UA with dasatinib + quercetin or other senolytics for a "senolytic protocol" is community speculation, not evidence.
  • Long-term mitophagy activation safety. Multi-decade chronic mitophagy activation has not been studied. Theoretical concern: chronic activation of any quality-control pathway could in principle produce maladaptation. Empirical 5+ year Mitopure user data has not surfaced safety signals, but this is a relatively new compound by long-horizon standards.
  • Verdict-confidence honesty. I am marking this OPTIONAL-ADD with MEDIUM-HIGH evidence confidence but LOW expected delta for Dylan's demographic. This is one of the few longevity supplements with genuinely strong human RCT data — the evidence base is materially better than 90% of the supplement market. The honest hedge is that the trials don't speak to young trained athletes specifically, and Dylan's particular profile is the least likely demographic to see clear benefit. What would change verdict to STRONG-CANDIDATE now:
    • Confirmed urinary non-producer status post-pomegranate-load test → clear physiological rationale to fill
    • Positive RCT readout in young trained population (not yet planned that I can find)
    • Pre/post C-acylcarnitine panel from a personal trial showing meaningful biomarker shift
  • What would change verdict to SKIP:
    • Confirmed metabotype A producer status + 4-month personal trial showing zero effect
    • Emerging long-term safety signal (none currently)
▸ Verdict change log
  • 2026-05-06 — Initial verdict: OPTIONAL-ADD (MEDIUM-HIGH confidence in evidence; LOW expected delta for Dylan's demographic). Urolithin A is the most-evidenced longevity supplement available OTC as of May 2026 — three independent human RCTs (Andreux 2019 Phase 1 mechanism, Singh 2022 Phase 2 muscle endurance, Liu 2022 Phase 2 older-adult muscle) consistently show measurable improvements in mitochondrial gene expression, plasma C-acylcarnitine biomarkers, and modest muscle endurance gains in older or sedentary adults at 500–1000 mg/day. Mechanism (selective mitophagy via PINK1/Parkin + downstream mitochondrial biogenesis via PGC-1α) is well-characterized and translated from rodents to humans (rare for a supplement). Microbiome producer status is the dominant variable — ~30–40% of Western adults are metabotype 0 non-producers and represent the strongest physiological case for direct supplementation. For Dylan's profile (20yo MMA athlete, brain priority, longevity #3, recovery #4): age-stratified evidence pattern places him opposite the trial demographic; young trained mitochondria have limited room for benefit. Best-case use: test urinary urolithin metabolite status post-pomegranate-load → if non-producer, upgrade to STRONG-CANDIDATE and run 500 mg/day continuous trial; if producer, defer to age 30+ revisit. Generic UA (Renue By Science 500 mg/day, $50/mo) is the best-value entry point; Mitopure ($80/mo) is the trial-validated formulation worth paying premium for if budget allows. No interactions, no cycling required, exceptionally clean safety profile. For 50+ longevity protocols: PRIMARY-PICK among longevity supplements with HIGH confidence as anchor of mitochondrial peptide/molecule stack alongside SS-31, NAD+ precursors, spermidine.
▸ Open questions / gaps Open
  1. Dylan's microbiome producer status. Action item: order urinary urolithin A glucuronide post-pomegranate-load test from a specialty lab (ZRT, Genova, Doctor's Data) when convenient. Result is binary-meaningful: non-producer → meaningful gap to fill, upgrade verdict; producer → likely lower marginal value, defer.
  2. Young-athlete RCT on UA does not exist. No published trial tests UA in 18–30 trained adults on athletic performance endpoints. The closest analog is the Singh 2022 middle-aged sedentary cohort, which showed modest fatigue-resistance gain — translation to young trained populations is speculative. Watch for new trials targeting athletic populations (none announced as of May 2026).
  3. Effect on subconcussive impact recovery / brain-protection claims. Mitochondrial quality is plausibly relevant to cumulative subconcussive impact recovery in MMA athletes (mitochondrial dysfunction is a documented feature of post-traumatic neurology). No direct UA brain / TBI trial in humans. Rodent TBI-recovery models show positive UA signal — interesting hypothesis, no human data. For Dylan's brain-priority framing, this is the most interesting unstudied angle.
  4. Mitopure premium vs generic UA. Need rigorous head-to-head bioavailability + functional comparison. Vendor-funded data is conflicted; independent comparisons are limited. Practical recommendation defaults to generic for cost-effectiveness but premium for risk-averse cases.
  5. Long-term (5+ year) safety profile. Mitopure has been on-market since ~2020; multi-decade horizons unstudied. No emerging signals but also no comprehensive longitudinal cohort.
  6. Synergy with exercise stimulus. The most compelling theoretical use is "training + UA = additive mitochondrial adaptation in trained populations." Not validated. Would require young-athlete RCT with training arm.
  7. Stacking evidence for UA + spermidine + NAD precursors. Community / longevity-protocol architecture stacks these three as the "mitochondrial layer," but no controlled trial has tested the stack vs individual components. Mechanistically reasonable; empirically untested.
  8. Cognition endpoint trials. Multiple animal models suggest UA may benefit age-related cognitive decline; no published human cognitive RCT. This is a major open question for the longevity-supplement field generally and would substantially change verdict for brain-priority users like Dylan.
  9. Pomegranate-load standardization. No single standard pomegranate juice / extract dose for producer-status testing across labs. Clinical-research convention is ~250–500 mL pomegranate juice; lab-specific protocols vary. Worth confirming with chosen testing lab before ordering.
  10. Cross-individual response variability. Even at validated doses, ~25–30% of trial participants showed minimal response. Pre/post biomarker panels (acylcarnitines) are the cleanest individual-response confirmation. Subjective signal alone is unreliable at this evidence tier.
▸ Sources (full, with our context)
Back to compact view